Using targeted therapy via genomic tumor testing for patients suffering from the most common type of lung cancer can help transform treatment for the disease, a new study conducted by researchers at Memorial Sloan Kettering reveals. The Lung Cancer Mutation Consortium (LCMC), composed of a group of 14 US hospitals, incorporated tumor genotyping into therapeutic decision-making for patients with lung adenocarcinomas. An oncogenic driver was detected in 64 percent ...
via Medindia Health News
More READ 
Lake forest health and fitness http://ift.tt/1r8CHUJ
No comments:
Post a Comment